Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
第一作者:
L Rhoda,Molife
第一单位:
Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Sciences, Institute of Cancer Research/Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK.
作者:
医学主题词
老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);人类(Humans);吲哚类(Indoles);男(雄)性(Male);中年人(Middle Aged);肿瘤转移(Neoplasm Metastasis);肿瘤分期(Neoplasm Staging);喹唑啉类(Quinazolines);治疗结果(Treatment Outcome)
DOI
10.2217/fon.13.250
PMID
24490608
发布时间
2018-12-02
- 浏览38
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



